Mick Hunter
Chief Scientific Officer and Director of Developme
dermatology
atopix
Netherlands
Biography
Dr Mick Hunter has responsibility for drug discovery and development in Atopix. He has over 28 years experience in Pharmaceutical and Biotech R&D. He has spent the past 12 years working on the discovery and development of antinflammatory and respiratory drugs. He is also Director of Discovery at Oxagen Ltd. Mick has led Atopix CRTH2 antagonist discovery and development program from concept to Phase IIb.Mick has experience of leading teams to identify IND candidates and managing them through early clinical development. He is familiar with regulatory environments and has managed biological pilot plants for GMP manufacture. Prior to joining Atopix, Mick held positions at Oxagen Ltd, British Biotech Pharmaceuticals (now Vernalis PLC) and at Searle Pharmaceuticals.
Research Interest
